Pharmacokinetics of pegylated recombinant human megakaryocyte growth and development factor in healthy volunteers and patients with hematological disorders

European Journal of Haematology

Volumn 73, Issue 4, 2004, Pages 269-279

  Tanaka, Hideji ^a   Takama, Hirotaka ^a   Arai, Yasumasa ^a   Azuma, Junichi ^b   Ohno, Ryuzo ^c   Ikeda, Yasuo ^d   Mizoguchi, Hideaki ^e  

^a KIRIN BREWERY CO LTD   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Clearance; Human; PEG rHuMGDF; Pharmacokinetics; Thrombopoietin

Indexed keywords

CELL RECEPTOR; CYTARABINE; IDARUBICIN; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; MITOXANTRONE; PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BOLUS INJECTION; CELL LINEAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERSTITIAL FLUID; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NONLINEAR MIXED EFFECT MODELING TECHNIQUE; NONLINEAR SYSTEM; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA; STATISTICAL ANALYSIS; STATISTICAL MODEL; STEADY STATE; THROMBOCYTE; THROMBOCYTE COUNT;

CASE-CONTROL STUDIES; HEMATOLOGIC DISEASES; HUMANS; PLACEBOS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; THROMBOPOIETIN;

EID: 4644297768     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00288.x     Document Type: Article

References (41)

1. DE SAUVAGE FJ, HASS PE, SPENCER SD et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MPL ligand. Nature 1994;369:533-538.
2. LOK S, KAUSHANSKY K, HOLLY RD et al. Cloning and expression of murine thrombopoietin cDNA and Stimulation of platelet production in vivo. Nature 1994;369:565-568.
3. KAUSHANSKY K, LOK S, HOLLY RD et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-MPL ligand thrombopoietin. Nature 1994;369:568-571.
4. BARTLEY TD, BOGENBERGER J, HUNT P et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MPL. Cell 1994;77:1117-1124.
5. KUTER DL, BEELER DL, ROSENBERG RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91:11104-11108.
6. KATO T, OGAMI K, SHIMADA Y et al. Purification and characterization of thrombopoietin. J Biochem 1995;118: 229-236.
7. SUNGARAN R, MARKOVIC B, CHONG BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997;89:101-107.
8. FARESE AM, HUNT P, BOONE T, MACVITTIE J. Recombinant human megakaryocyte growth and development factor stimulates thrombopoiesis in normal nonhuman primates. Blood 1995;86:54-59.
9. BASSER RL, RASKO JEJ, CLARKE K et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996;348:1279-1281.
10. O'MALLEY CJO, RASKO JEJ, BASSER RL et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996;88:3288-3298.
11. FANUCCHI M, GLASPY J, CRAWFORD J et al. Effects of polyethylene-glycol- conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Eng J Med 1997;336:404-409.
12. BASSER RL, RASKO JEJ, CLARKE K et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997;89:3118-3128.
13. DE BOER RH, ROSKOS LK, CHEUNG E et al. Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans. Growth Factors 2000;18:215-216.
14. HARKER LA, ROSKOS LK, MARZEC UM et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000;95:2514-2522.
15. VADHAN-RAJ S, MURRAYM LJ, BUESO-RAMOS C et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673-681.
16. WOLFF SN, HERZIG R, LYNCH J et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant 2001;27:261-268.
17. NASH RA, KURZROCK R, DIPERSIO J et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000;6: 25-34.
18. VADHAN-RAJ S, KAVANAGH JJ, FREDMAN RS et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomized cross-over study. Lancet 2002;359:2145-2152.
19. NOMURA S, DAN K, HOTTA T, FUJIMURA K, IKEDA Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002;100:728-730.
20. TAHARA T, USUKI K, SATO H et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haemato 1996;93:783-788.
21. KAUSHANSKY K. Thrombopoietin: The primary regulator of platelet production. Blood 1995;86:419-431.
22. FIELDER PJ, GURNEY AL, STEFANICH ES et al. Regulation of thrombopoietin levels by c-mp1-mediated binding to platelets. Blood 1996;87:2154-2161.
23. STEFANICH E, SENN T, WIDMER R, FRATINO C, KELLER GA, FIELDER PJ. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood 1997;89:4063-4070.
24. LI J, XIA Y, KUTER DJ. Interaction of thrombopoietin with the platelet c-mp1 receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999;106:345-356.
25. TANAKA H, TOKIWA T. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor studied in the rat by a sandwich enzyme-linked immunosorbent assay. J Pharmacol Exp Ther 1990;255:724-729.
26. KUWABARA T, KATO Y, KOBAYASHI S, SUZUKI H, SUGIYAMA Y. Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (Nartograstim): Species differences among rats, monkeys and humans. J Pharmacol Exp 1994;271:1535-1543.
27. CHAPEL S, VENG-PEDERSEN P, JOHL RJ, SCHMIDT RL, MCGUIRE EM, WIDNESS JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001;298:820-824.
28. MARSH JCW, GIBSON FM, PRUE RL et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996;95:605-610.
29. USUKI K, TAHARA T, IKI S et al. Serum thrombopoietin level in various hematological diseases. Stem Cells 1996;14:558-565.
30. EMMONS RVB, REID DM, COHEN RL et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-4071.
31. CHANG M, SUEN Y, MENG G et al. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood 1996;88:3354-3362.
32. KOSUGI S, KURATA Y, TOMIYAMA Y et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996;93:704-706.
33. KUNISHIMA S, TAHARA T, KATO T, KOBAYASHI S, SAITO H, NAOE T. Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders. Eur J Haematol 1996;57:68-71.
34. ICHIKAWA N, ISHIDA F, SHIMODAIRA S, TAHARA T, KATO T, KITANO K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost 1996;76:156-160.
35. SHIMODAIRA S, ISHIDA F, ICHIKAWA N et al. Serum thrombopoietin (c-Mp1 ligans) levels in patients with liver cirrhosis. Thromb Haemost 1996;76:545-548.
36. MARTIN TG, SOMBERG KA, MENG G et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997;127:285-288.
37. CHANG M, QIAN JX, LEE SM et al. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice. Blood 1999;93:2515-2524.
38. CERUTTI A, CUSTODI P, DURANTI M, NORIS P, BALDUINI AL. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997;99:281-284.
39. MURONE M, CARPENTER DADE SAUVAGE FJ. Hematopoietic deficiencies in c-mp1 and TPO knockout mice. Stem Cells 1998;16:1-6.
40. NAGASAWA T, HASEGAWA Y, SHIMIZU S et al. Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects. Br J Haematol 1998;101:242-244.
41. ZENT CS, RATAJCZAK J, RATAJCZAK M, ANASTASI J, HUFFMAN PC, GEWIRTZ AM. Relationship between megakaryocyte mass and serum thrombopoietin levels as revealed by a case of cyclic amegakaryocytic thrombocytopenic purpura. Br J Haematol 1999;105:452-458.